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Inhibitory phosphorylation of the APC regulator Hct1 is
controlled by the kinase Cdc28 and the phosphatase Cdc14
Sue L. Jaspersen, Julia F. Charles and David O. Morgan
Background: Exit from mitosis requires inactivation of mitotic cyclin-dependent
kinases (CDKs). A key mechanism of CDK inactivation is ubiquitin-mediated
cyclin proteolysis, which is triggered by the late mitotic activation of a ubiquitin
ligase known as the anaphase-promoting complex (APC). Activation of the APC
requires its association with substoichiometric activating subunits termed Cdc20
and Hct1 (also known as Cdh1). Here, we explore the molecular function and
regulation of the APC regulatory subunit Hct1 in Saccharomyces cerevisiae.
Results: Recombinant Hct1 activated the cyclin–ubiquitin ligase activity of APC
isolated from multiple cell cycle stages. APC isolated from cells arrested in G1,
or in late mitosis due to the cdc14-1 mutation, was more responsive to Hct1
than APC isolated from other stages. We found that Hct1 was phosphorylated
in vivo at multiple CDK consensus sites during cell cycle stages when activity
of the cyclin-dependent kinase Cdc28 is high and APC activity is low. Purified
Hct1 was phosphorylated in vitro at these sites by purified Cdc28–cyclin
complexes, and phosphorylation abolished the ability of Hct1 to activate the
APC in vitro. The phosphatase Cdc14, which is known to be required for APC
activation in vivo, was able to reverse the effects of Cdc28 by catalyzing Hct1
dephosphorylation and activation. 
Conclusions: We conclude that Hct1 phosphorylation is a key regulatory
mechanism in the control of cyclin destruction. Phosphorylation of Hct1
provides a mechanism by which Cdc28 blocks its own inactivation during 
S phase and early mitosis. Following anaphase, dephosphorylation of Hct1 by
Cdc14 may help initiate cyclin destruction. 
Background
Exit from mitosis in Saccharomyces cerevisiae requires the
ubiquitin-dependent proteolysis of multiple proteins,
including the anaphase inhibitor Pds1 and the mitotic
cyclins (Clbs) [1,2]. A key step in the ubiquitination of
these proteins is catalyzed by a multi-subunit ubiquitin
ligase known as the anaphase-promoting complex (APC;
reviewed in [3,4]), the activity of which increases in late
mitosis and remains high throughout G1 [5–7]. Mechanisms
governing APC activation in late mitosis are poorly under-
stood. In higher eukaryotes, phosphorylation of APC sub-
units is thought to promote APC activity [8–13]. In budding
yeast, phosphorylation of the APC has not been reported,
but there is evidence that the protein kinase Cdc28 inhibits
APC-dependent cyclin proteolysis in vivo [14].
The function of the APC is regulated by the WD40-repeat
proteins Cdc20 and Hct1 (also known as Cdh1). On the
basis of genetic evidence from budding yeast, it is thought
that Pds1 degradation at the metaphase–anaphase transi-
tion is promoted by Cdc20, after which Hct1 stimulates
proteolysis of the cyclin Clb2 [15–18]. Recent biochemical
evidence from vertebrates suggests that Cdc20 and Hct1
act as substoichiometric APC subunits that stimulate ubiq-
uitin ligase activity and may also contribute to substrate
recognition [19–22]. 
As key regulators of APC function, Cdc20 and Hct1 are
likely to be critical targets for many mitotic regulatory
pathways. Cdc20 appears to be regulated at multiple
levels. It is an unstable protein whose concentration peaks
in mitosis, after which APC-dependent proteolysis leads
to decreased levels in G1 [16,19–21,23]. In cells arrested
in metaphase by spindle damage, Cdc20 function is inhib-
ited by association with checkpoint signaling proteins
[21,22,24,25]. The regulation of Hct1 activity, however, is
poorly understood. Hct1 levels do not change during the
cell cycle, although in human cells the amount of Hct1
associated with the APC increases in G1 [19,21,23]. Thus,
post-translational mechanisms probably regulate Hct1-
dependent stimulation of APC activity.
Activation of the cyclin–ubiquitin ligase activity of the
APC in late mitosis also requires the function of a large
family of regulatory proteins, including the protein kinase
Cdc15 [26,27], the Polo-like kinase Cdc5 [6,16,28], and
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the protein phosphatase Cdc14 [29,30]. Cells lacking the
function of these proteins arrest in late mitosis with high
cyclin levels and profound defects in Hct1-dependent
APC activity [6,27]. The mechanism by which the late
mitotic regulatory proteins promote cyclin-specific APC
activation is not clear.
Here, we analyze Hct1 phosphorylation and its effects on
the ability of Hct1 to act as an activator of the cyclin–ubiq-
uitin ligase activity of the APC. We found that Cdc28-
dependent phosphorylation occurs at multiple sites on
Hct1 in vivo. Phosphorylation of Hct1 by Cdc28 com-
pletely inhibited Hct1 activity in vitro, providing a mecha-
nism by which Cdc28 blocks its own inactivation. The
inhibitory phosphorylation of Hct1 was removed by the
phosphatase Cdc14, suggesting that the requirement for
Cdc14 in late mitosis is due, at least in part, to its ability to
activate Hct1. 
Results
Activation of the APC by Hct1 in vitro
We first set out to explore mechanisms of APC regulation
by analyzing the ability of purified Hct1 to activate puri-
fied APC in vitro. Our initial step was to develop a conven-
tional purification strategy to purify active APC from
G1-arrested cells and inactive APC from cells that had
been arrested in late mitosis by the cdc15-2 mutation
(Figure 1). In both preparations, we observed approxi-
mately 12 co-purifying subunits that correspond to the 12
subunits observed in previous reports (Figure 1a; [31,32]).
During the purification, the G1 APC maintained activity
whereas the anaphase APC remained inactive (Figure 1b),
suggesting that differences in activity were due to intrinsic
subunits or modifications. In comparisons of several
preparations from G1 and anaphase cells, however, we did
not detect any differences in APC subunit composition or
the electrophoretic mobility of any subunit on polyacry-
lamide gels (Figure 1a). Thus, APC activity in these
experiments must be influenced by substoichiometric
subunits or by modifications that do not affect gel mobility
under these conditions. 
Cyclin–ubiquitin ligase activity of the purified APC from
cdc15-2 cells was potently stimulated by hexahistidine-
tagged Hct1 (Hct1–His6) purified from baculovirus-
infected insect cells (Figure 2a). Thus, Hct1 alone is
sufficient to activate the cyclin–ubiquitin ligase activity of
the APC. Hct1 was also able to activate the APC isolated
by immunoprecipitation from several other late mitotic
mutants (cdc5-1, cdc14-1, dbf2-2 and tem1-3; Figure 2b). In
addition, Hct1 activated the APC from cells arrested at the
DNA replication checkpoint following treatment with
hydroxyurea (HU) and at the spindle assembly checkpoint
following treatment with nocodazole, indicating that the
APC inhibitory mechanisms acting at these checkpoint
arrests do not completely block APC responsiveness to
Hct1 (Figure 2b). Similarly, Hct1 activated the APC from
a cdc20-1 mutant, indicating that no previous function of
Cdc20 is required for Hct1 responsiveness in vitro
(Figure 2b). Finally, we observed that Hct1 was able to
hyperactivate the active APC isolated from cells arrested
in G1 with the mating pheromone α-factor (Figure 2b).
Thus, a major fraction of the APC from multiple cell cycle
stages can be activated by Hct1.
Hct1 responsiveness of the APC increases in late mitosis
Analysis of APC activation over a range of Hct1 concentra-
tions in vitro revealed that differences in Hct1 responsive-
ness exist at different cell cycle stages (Figure 2c–f). We
analyzed activation of the APC from cells arrested in
metaphase (nocodazole), anaphase (cdc15-2), or G1 (α-factor),
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Figure 1
Purification of the APC from cells arrested in anaphase due to the
cdc15-2 mutation or in G1 due to the cdc28-13 mutation. (a) Peak
fractions from the final purification step were pooled and analyzed by
electrophoresis on an 8.5% polyacrylamide gel, followed by silver
staining. In multiple preparations, we observed twelve subunits similar
in mobility to those seen in previous reports [31,32]. Nine subunits
are marked to the left; the three smallest subunits are apparent only
on higher percentage gels. Proteins migrating at about 50 kDa
(asterisk) are contaminants that do not co-purify with the APC.
Protein markers are shown to the right. (b) The cyclin–ubiquitin ligase
activities of purified anaphase and G1 APCs were measured by
immunoprecipitating equivalent amounts of APC with 12CA5 antibody
(which recognizes the hemagglutinin (HA)-tagged Cdc23 subunit in
these preparations) and measuring ubiquitination of a 125I-labeled cyclin
fragment. The asterisk indicates a non-specific background band.
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and in four independent experiments we found that the
Hct1 concentration required for half-maximal activation of
the G1 APC (5 nM) was consistently fourfold lower than
that required for half-maximal activation of the APC from
cells arrested by nocodazole or the cdc15-2 mutation
(20 nM; Figure 2c,d). 
Interestingly, analysis of the APC from three late mitotic
mutants (cdc15-2, cdc5-1 and cdc14-1) revealed that all late
mitotic mutants do not arrest with equally responsive APC
(Figure 2e,f). Whereas the APC from cdc5-arrested cells
behaved similarly to that of cdc15-arrested and nocodazole-
arrested cells (half-maximal activation at 20–25 nM Hct1),
the APC from the cdc14-1 mutant exhibited a higher Hct1
sensitivity, similar to that seen in G1-arrested cells (half-
maximal activation at 5 nM Hct1). 
The simplest interpretation of these experiments is that
increasing Hct1 concentration leads to increased levels of
Hct1 binding to the APC, which is then reflected in stimu-
lation of APC activity. As these experiments were per-
formed at very low APC concentrations (roughly
nanomolar), the Hct1 concentration at which half-maximal
stimulation occurs probably provides an estimate of the
Hct1–APC affinity, although more direct binding analyses
will be required to assess this possibility rigorously. Never-
theless, these results suggest that APCs from cdc14-arrested
and G1-arrested cells have a relatively high affinity for Hct1.
Hct1 is phosphorylated by Cdc28
Our results indicate that the APC from multiple cell cycle
stages is responsive to Hct1 in vitro, raising the question of
why Hct1 does not activate these APCs in vivo. Hct1 levels
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Activation of APC by recombinant Hct1. (a) Increasing amounts of
purified Hct1–His6 were added to approximately 6 nM APC purified
from cdc15-2 cells, and cyclin–ubiquitin ligase activity was measured.
The asterisk indicates a non-specific background band. (b) Cells were
arrested at various cell cycle stages with the indicated temperature-
sensitive mutations or by treatment with α-factor (αf), hydroxyurea
(HU), or nocodazole (Noc). The hct1∆ strain was grown
asynchronously at 23°C. APC was immunoprecipitated from 250 µg
yeast lysate with anti-Cdc26 antibodies (a gift of L. Hwang), and
incubated with either 15 nM Hct1–His6 (+) or buffer (–), followed by
measurement of cyclin–ubiquitin ligase activity. Control experiments
were performed without added yeast lysate (–APC). (c,d) APC was
immunoprecipitated from lysates (70 µg) of wild-type cells treated with
α-factor (αf) or nocodazole (Noc), or from cdc15-2 cells arrested at
37°C (cdc15). Recombinant Hct1–His6 was added in increasing
amounts, and APC activity was measured. In (c), the average APC
activity in four independent experiments is expressed as a percentage
of maximum activity for that APC. In (d), the data have been linearized
with a double-reciprocal plot. Standard errors are indicated, although
in most cases they were smaller than the diameters of the symbols.
We estimate that APC concentrations in all four experiments were in
the nanomolar range. (e,f) APC was immunoprecipitated from lysates
(70 µg) of cdc5-1, cdc15-2 and cdc14-1 cells arrested at 37°C.
Following incubation with increasing amounts of Hct1, APC activity in
a representative experiment was analyzed as in (c) and (d). Similar
results were obtained in three independent experiments.
are constant during the normal cell cycle [23], indicating
that Hct1 activity in vivo may be regulated by post-transla-
tional modification. To explore potential Hct1 modifica-
tions, we constructed a strain containing an integrated copy
of a gene encoding a hemagglutinin (HA) epitope-tagged
form of Hct1 under the control of the GAL promoter. At
least three electrophoretic mobility forms of Hct1–HA
were apparent in lysates from these cells: a closely spaced
doublet at approximately 65 kDa and a heterogeneous
series of bands migrating slightly slower than the doublet
(Figure 3a, lane 2). The diffuse upper band, as well as the
top band of the doublet, disappeared upon treatment of
Hct1 immunoprecipitates with λ-phosphatase (Figure 3a),
demonstrating that Hct1 is phosphorylated in vivo. The
diffuse upper form of Hct1 was most prominent in cells
arrested in S phase and mitosis, and was not detectable in
cells arrested in G1 (Figure 3b). Thus, the presence of this
form is inversely correlated with APC activity, suggesting
that it may represent an inhibitory modification. 
Hct1 phosphorylation increased during cell cycle stages
when Cdc28 activity is known to be high (S and M phases),
and examination of the predicted amino acid sequence of
Hct1 revealed the presence of six consensus Cdc28 phos-
phorylation sites (S/T*–P–X–K/R, in single-letter amino
acid code where X represents any amino acid). We con-
structed a version of Hct1–HA in which these sites
(serines 16, 42, 227, 239 and 436, and threonine 176)
were mutated to alanine (termed the Hct1-28A mutant).
When this mutant was expressed in asynchronous yeast
cells, only the lower two mobility forms of Hct1 were
observed (Figure 3a). Similarly, in cells arrested in S or
M phases the diffuse upper Hct1 band was absent in the
Hct1-28A mutant (Figure 3b). We conclude that Hct1 is
phosphorylated in vivo at Cdc28 consensus sites when
Cdc28 activity is high.
To further document a role for Cdc28 in Hct1 phosphory-
lation, we showed that purified, baculovirus-derived
Hct1–His6 was efficiently phosphorylated in vitro by puri-
fied Cdc28–Clb2 complexes (Figure 4a), and that phos-
phorylation by Cdc28 led to a heterogeneous
electrophoretic mobility shift similar to the Hct1 mobility
shifts observed in vivo (Figure 4a,b). Quantitation of phos-
phate incorporation in these experiments indicated that
approximately 3–5 phosphates were transferred to
Hct1–His6 by Cdc28–Clb2. 
We also analyzed phosphorylation of the mutant Hct1-28A
protein by Cdc28–Clb2 in vitro (Figure 4a). Because the
Hct1-28A protein could not be expressed at high levels in
insect cells and was therefore less homogeneous upon
purification, phosphorylation of the protein by a contami-
nating kinase was more pronounced; nevertheless, mutation
of the six Cdc28 sites abolished over 80% of the Cdc28-
dependent Hct1 phosphorylation at high Cdc28–Clb2 con-
centrations. On the basis of this result, as well as our
evidence from intact cells, we conclude that Hct1 is phos-
phorylated by Cdc28 in vivo during S and M phases, and
that the phosphorylation occurs at several cyclin-dependent
kinase (CDK) consensus sites in the protein. 
Five of the six CDK consensus sites in Hct1 are found in
the amino-terminal half of the protein, whereas one site
(Ser436) is located within the WD40 repeats of the
carboxy-terminal half. We therefore constructed another
Hct1 mutant in which only the five amino-terminal sites
were changed to alanine. Mutation of these sites also abol-
ished the diffuse upper forms of Hct1, suggesting that
these five sites are the major sites of Cdc28-dependent
phosphorylation in vivo (data not shown).
Cdc28-dependent phosphorylation inactivates Hct1
To assess the effects of Cdc28–Clb2-dependent phospho-
rylation on Hct1 activity, we developed methods that
allowed us to treat Hct1–His6 with Cdc28–Clb2 and then
re-purify it (Figure 4b). Phosphorylation of Hct1–His6 dra-
matically inhibited its ability to stimulate the cyclin–ubiq-
uitin ligase activity of the purified APC from cdc15 cells
(Figure 4c). Treatment of the Hct1-28A mutant with
Cdc28–Clb2 kinase had no effect on its ability to stimulate
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Figure 3
Hct1 phosphorylation in vivo at Cdc28 consensus sites. (a) Wild-type
strains containing GAL–HCT1–HA or GAL–HCT1-28A–HA (a mutant
in which the six Cdc28 consensus sites are changed to alanine) were
grown in galactose for 2.5 h. Wild-type or mutant Hct1–HA proteins
were immunoprecipitated using the anti-HA antibody from cell lysates
(500 µg) and treated with phosphatase buffer plus phosphatase
inhibitors (lanes 2,5), 100 U λ-phosphatase (lanes 3,6), or both
λ-phosphatase and phosphatase inhibitors (lanes 4,7). Lane 1 is an
immunoprecipitate from a lysate of cells lacking the tagged Hct1.
Immunoprecipitates were immunoblotted with the anti-HA antibody
16B12. (b) The same strains as in (a) were arrested in α-factor (αf),
hydroxyurea (HU), or nocodazole (Noc), or left untreated as
asynchronous cultures (A). Galactose was then added to 2%, except
in the uninduced asynchronous control (U). Anti-HA immuno-
precipitates of cell lysates were then probed by immunoblotting with
anti-HA antibody 16B12. Partial Hct1 degradation in this experiment
resulted in the appearance of anti-HA-reactive bands below the main
Hct1 bands. In (a,b), the positions of unphosphorylated (Hct1–HA)
and phosphorylated (P-Hct1–HA) forms are marked.
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APC activity (Figure 4d). We conclude that phosphory-
lation by Cdc28–Clb2 severely impairs stimulation of
cyclin–ubiquitin ligase activity by Hct1.
To assess the role of Cdc28-dependent phosphorylation in
Hct1 function in vivo, we analyzed the effects of moderate
Hct1-28A expression on cell proliferation and cyclin
levels. Expression of Hct1-28A, but not of wild-type Hct1,
inhibited cell proliferation (Figure 5a) and caused a
decrease in Clb2 levels in cells arrested in mitosis with
nocodazole (Figure 5b). Expression of Hct1-28A was also
able to partially suppress the growth defect of the late
mitotic mutant cdc14-1 (Figure 5c), which is defective in
the activation of cyclin-specific ubiquitin ligase activity
[27]. These results are consistent with the possibility that
the Cdc28 phosphorylation sites in Hct1 are involved in
the negative regulation of APC activity.
The phosphatase Cdc14 dephosphorylates and activates Hct1 
Our results raise the possibility that activation of cyclin
destruction in late mitosis is triggered by dephosphoryla-
tion of inhibitory sites on Hct1. The phosphatase Cdc14 is
an excellent candidate for the Hct1 phosphatase, as it is
required for late mitotic APC activation and cyclin
destruction [27], and is upregulated during mitosis [29].
The fact that the growth defect in cdc14-1 cells is rescued
by Hct1-28A expression (Figure 5c) also supports the pos-
sibility that Hct1 is a key target of Cdc14.
We tested the ability of Cdc14 to dephosphorylate Hct1 by
adding purified glutathione-S-transferase (GST)–Cdc14 to
preparations of Hct1 that had been radioactively phospho-
rylated by purified Cdc28–Clb2 (Figure 6a). In these
experiments, Hct1 was labeled by Cdc28 at approximately
one site per molecule, resulting in only a partial shift in
mobility on the gel. Under these conditions, small amounts
of GST–Cdc14 rapidly catalyzed the removal of 50% of the
Cdc28-dependent phosphorylation of Hct1, resulting in
the collapse of the labeled band into the high mobility
form (Figure 6a). We also assessed the Hct1 phosphatase
activity of Cdc14 by measuring the radioactive phosphate
released from Hct1 into solution. Here, Cdc14 again cat-
alyzed the release of phosphate from Hct1 in a dose-
dependent manner (Figure 6b).
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Figure 4
Phosphorylation of Hct1 by Cdc28–Clb2
abolishes its ability to activate the APC.
(a) Increasing amounts of Cdc28–Clb2 were
tested for their ability to phosphorylate 150 ng
purified Hct1–His6 or the Hct1-28A–His6
mutant. Quantitation of phosphate
incorporation in these experiments indicated
that approximately 4.4 mol phosphate was
incorporated per mol wild-type Hct1–His6 at
the highest Cdc28–Clb2 concentrations; in
other experiments, phosphate incorporation
varied from 3 to 5 mol/mol. Control lanes of
samples with no added Hct1–His6 are
indicated (–). (b) Purified Hct1–His6 (3 µg)
was incubated with ATP and 10 µg
Cdc28–Clb2 complex immobilized by
immunoprecipitation on beads (lane 2). To
control for contaminating kinases, Hct1–His6
was incubated in a reaction with ATP and
beads alone (lane 1); to verify that the effects
of Cdc28–Clb2 on Hct1–His6 were
dependent on Cdc28–Clb2 kinase activity,
ATP was omitted from the kinase reaction
(lane 3). Following removal of the Cdc28–Clb2
complex, 25% of the reaction was analyzed by
gel electrophoresis and Coomassie blue
staining. The positions of unphosphorylated
(Hct1–His6) and phosphorylated (P-
Hct1–His6) forms are marked. (c) The three
Hct1–His6 preparations shown in (b) were
incubated in solution with 6 nM APC purified
from cdc15-2-arrested cells, and
cyclin–ubiquitin ligase activity in the reaction
was measured. The quantitation of the APC
activity as a percentage of maximum is shown
below the gel. (d) Wild-type Hct1–His6 and
mutant Hct1-28A–His6 (3 µg) were treated
with Cdc28–Clb2 (10 µg), and activation of a
purified cdc15-2 APC was tested as in (c).
Because the mutant Hct1–His6 purified from
insect cells appears unstable and is not as
effective in APC activation as the wild-type
protein, wild-type Hct1–His6 was diluted 1 in
30 after treatment with kinase and prior to
incubation with the APC. Average APC activity
in four independent experiments is shown as
percentage of maximal activity achieved with
untreated Hct1–His6. 
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Most importantly, treatment of Cdc28-phosphorylated
Hct1 with Cdc14 partially restored the ability of Hct1 to
activate the APC in vitro (Figure 6c). There was no effect
when we added GST–Cdc14 proteins containing point
mutations in the active site (C283S or C283S/R289A),
which are known to abolish phosphatase activity [30].
Thus, Cdc14 is able to dephosphorylate key Cdc28-
dependent inhibitory sites on Hct1. Addition of purified
GST–Cdc14 alone did not stimulate the inactive APC
from cdc15-2 cells, and pre-incubation of inactive APC
with GST–Cdc14 did not affect subsequent activation by
purified Hct1 (data not shown). Thus, Cdc14 does not
have a direct action on the APC itself in our experiments. 
A fraction of phosphorylated Hct1 in these experiments
appeared resistant to dephosphorylation by Cdc14
(Figure 6a). Similarly, the activity of phosphorylated Hct1
was not fully restored by Cdc14 treatment (Figure 6c). It
therefore appears that all Cdc28-dependent phosphoryla-
tion sites on Hct1 are not equally effective substrates for
Cdc14 under these conditions.
To further explore the function of Cdc14, we added
GST–Cdc14 to crude lysates prepared from cdc14-arrested
cells expressing the gene encoding Hct1–HA from the
GAL promoter (Figure 7a). Cdc14 treatment abolished the
Cdc28-dependent low mobility forms of Hct1, resulting in
a collapse of the diffuse Hct1 band to the doublet seen in
G1 cells (Figure 7a, upper panel). APC activity in the
lysate increased (Figure 7a, lower panel). Addition of large
quantities of λ-phosphatase had only slight effects on
Hct1 mobility and no effect on APC activity, suggesting
that Cdc14 is a more specific Hct1 phosphatase under
these conditions. APC activation was also seen when
GST–Cdc14 was added to lysates of cdc14-arrested cells
lacking overexpressed Hct1–HA (Figure 7b), showing that
APC re-activation by Cdc14 in these experiments is not
dependent on high levels of exogenous Hct1. 
We next confirmed the role of Cdc14 in Hct1 dephospho-
rylation in vivo. Overexpression of CDC14 in mitotically
arrested cells abolished Hct1 phosphorylation and trig-
gered APC activation and Clb2 destruction (Figure 7c).
Similar results were obtained in cells lacking the CDK
inhibitor Sic1 (Figure 7c), the levels of which are known
to increase in cells overexpressing CDC14 [33]. Thus,
Cdc14 does not trigger Hct1 dephosphorylation indirectly
by decreasing Cdc28 activity. 
Discussion
We conclude that inhibitory phosphorylation of Hct1 is an
important mechanism of APC regulation. Several lines of
evidence suggest that Cdc28–cyclin complexes are respon-
sible for catalyzing this phosphorylation. First, Hct1
undergoes phosphate-dependent mobility shifts during
cell cycle stages when Cdc28 is known to be active, and
these shifts are abolished when Cdc28 consensus phospho-
rylation sites in Hct1 are changed to non-phosphorylatable
alanine residues. Second, purified Cdc28–Clb2 complexes
catalyze phosphorylation of a large subset of these sites in
vitro. Third, Cdc28-dependent phosphorylation inhibits
Hct1 function in vitro, explaining previous observations
that the activities of Cdc28 and APC are inversely corre-
lated during the cell cycle [5], that inhibition of Cdc28
activity is sufficient to allow nocodazole-arrested cells to
exit mitosis, and that artificial induction of Cdc28–Clb2
kinase activity in G1 cells leads to Clb2 stabilization [14]. 
While this manuscript was in preparation, Zachariae et al.
[34] published evidence also suggesting that Hct1 phos-
phorylation by Cdc28 inhibits APC activity in vivo. They
also observed phosphate-dependent Hct1 mobility shifts
during cell cycle stages when Cdc28 activity is high, and
232 Current Biology, Vol 9 No 5
Figure 5
Effects of Hct1-28A in vivo. (a) Log-phase hct1∆ strains containing
vector, GAL–HCT1–HA or the mutant GAL–HCT1-28A–HA were
serially diluted twofold and spotted onto YPD (dextrose) and
YP/galactose-raffinose (galactose) plates. Plates were incubated for
2.5 days at 23°C. (b) The same strains used in (a) were grown to mid-
log phase, arrested with hydroxyurea, washed and treated for 2 h with
nocodazole. Galactose was added, and samples were harvested after
the indicated induction times for immunoblotting with the indicated
antibodies, with the anti-HA antibody detecting the Hct1–HA protein.
In all samples, greater than 90% of cells remained large-budded
throughout the experiment. Note that wild-type HCT1 overexpression
had little effect in these experiments, in contrast to results in previous
studies [17,18]. This may be due to differences in the expression level
achieved in our work, and may also indicate that the single carboxy-
terminal HA tag on Hct1 reduces Hct1 function. (c) Log-phase
cdc14-1 strains containing vector, GAL–HCT1–HA or the mutant
GAL–HCT1-28A–HA were serially diluted twofold and spotted onto
YP/galactose-raffinose plates. Plates were incubated for 3 days at
23°C or 4 days at 37°C. No growth was observed on control plates
containing dextrose at 37°C (data not shown).
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Vector
Hct1
Hct1-28A
(b)
01 2 4 01 2 40 12 4 Induction time (h)
Anti-Clb2
Vector Hct1 Hct1-28A
Anti-Cdc28
Current Biology   
Anti-HA
(c) 37°C23°C
Vector
Hct1
Hct1-28A
Research Paper  Control of Hct1 by Cdc28 and Cdc14 Jaspersen et al.    233
Figure 6
Cdc14 promotes Hct1 dephosphorylation
and APC activation. (a) Hct1–His6 (50 ng)
was incubated with [γ-32P]ATP and 20 ng
Cdc28–Clb2 complexes immobilized on
beads, or incubated with ATP in the presence
of beads alone. The soluble Hct1–His6 was
incubated for 30 min at 30°C with purified
GST or with the indicated amounts of purified
GST–Cdc14. The percentage of Cdc28-
dependent phosphate remaining on Hct1 is
indicated below the figure. (b) The
32P-phospholabeled form of Hct1–His6 (final
concentration 3 nM) was incubated for 5 min
at 25°C with GST or the indicated amounts of
GST–Cdc14. Proteins in the reaction were
precipitated with acid, and radioactivity in the
resulting supernatant was measured.
Background phosphate release (in the
presence of GST alone) has been subtracted.
Because phosphorylated Hct1 is not readily
prepared in large quantities, we could not use
saturating substrate concentrations, and the
rate of phosphate release in these
experiments (0.1–0.3 nmol mg–1 min–1) is
probably far below maximum. (c) Hct1–His6
(100 ng) was incubated with 20 ng
Cdc28–Clb2, either in the presence or
absence of 1 mM ATP. We then added the
indicated amounts of GST (lane G),
GST–Cdc14 (lanes marked 14), or
phosphatase-deficient mutant forms of
GST–Cdc14 (C283S, lane C;
C283S/R289A, lane C/R). After 30 min
incubation at 30°C, treated Hct1 was tested
for its ability to activate the cyclin–ubiquitin
ligase activity of the APC in anti-Cdc26
immunoprecipitates from 400 µg lysates of
cdc15-2 cells arrested at 37°C.
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Cdc14 promotes APC activation in crude cell extracts and in vivo.
(a) The indicated amounts of GST, GST–Cdc14, or λ-phosphatase
were added to cell lysates (1 mg) prepared from cdc14-1 cells
arrested at 37°C and expressing Hct1–HA from the GAL promoter.
Anti-HA immunoprecipitates were immunoblotted with anti-HA
antibody 16B12 (upper panel), or cyclin–ubiquitin ligase activity was
measured in anti-Cdc26 immunoprecipitates (lower panel). (b) The
indicated amounts of GST (lane G), GST–Cdc14 (lanes marked 14),
phosphatase-deficient GST–Cdc14 point mutants (lanes C and
C/R), or λ-phosphatase were added to cell lysates (1 mg) prepared
from cdc14-1 cells arrested at 37°C. Cyclin–ubiquitin ligase activity
was then measured in anti-Cdc26 immunoprecipitates. (c) Wild-type
(WT) or sic1∆ cells containing GAL–HCT1–HA alone or in
combination with GAL–CDC14 were arrested in mitosis by
treatment with 15 µg/ml nocodazole, followed by addition of
galactose (4%) for 3 h. APC activity was measured in anti-Cdc26
immunoprecipitates from 600 µg cell extract (upper panel). Clb2
protein was detected by western blotting with anti-Clb2 antibody
(middle panel). Hct1–HA protein was immunoprecipitated with anti-
HA antibodies from 1 mg cell extract and analyzed by western
blotting with anti-HA antibodies (lower panel). The positions of
unphosphorylated (Hct1–HA) and phosphorylated (P-Hct1–HA)
forms are indicated. 
found that Hct1 phosphorylation was inversely correlated
with cyclin destruction in vivo. Overexpression of an Hct1
mutant lacking CDK consensus phosphorylation sites
blocked cyclin accumulation in vivo. The mutant Hct1
protein was bound to the APC in vivo at cell cycle stages
when Cdc28 activity is high, suggesting that Cdc28-
dependent Hct1 phosphorylation blocks APC activation
by inhibiting the Hct1–APC interaction. 
We found that Cdc28-dependent Hct1 phosphorylation
was prevented by mutation of five residues in Hct1, while
Zachariae et al. [34] observed a complete loss of phospho-
rylation only when nine sites were mutated. This apparent
discrepancy is readily explained. Whereas Zachariae et al.
mutated all serines or threonines followed by a proline, we
focused on the subset of sites that also have a basic
residue two positions after the proline (as is often the case
in CDK substrates). Zachariae et al. observed a reduction
in Hct1 phosphorylation only when their mutations
included one or more of the basic sites that we mutated. 
Inhibitory Hct1 phosphorylation thus provides a mecha-
nism by which Cdc28 suppresses cyclin-specific APC
activity during S phase and early mitosis. It seems
unlikely, however, that this is the only mechanism govern-
ing APC activity. Additional regulatory modifications may
govern Hct1 function, as some Hct1 phosphorylation is
observed in the Hct1-28A mutant and in G1 cells
(Figure 3). In addition, cyclin destruction is probably con-
trolled in part by modification of the APC core itself, as
suggested by our observation (Figure 2c–f) that the APC
from cdc14-arrested and G1-arrested cells is more respon-
sive to Hct1 than the APC from other late mitotic
mutants. These results are reminiscent of recent evidence
in vertebrates that the affinity of the APC for Cdc20 varies
during the cell cycle [19,20], and are also consistent with
previous evidence that APC activity in vertebrates is regu-
lated by phosphorylation of core APC subunits [8–13]. 
On the basis of these considerations, we speculate that
some modification of the APC in late mitosis results in
enhanced affinity for Hct1 (Figure 8). Cdc14 is not
required for this modification, as the APC from cdc14 cells,
unlike that from cdc5 or cdc15 cells, displays the increased
Hct1 sensitivity that is seen in G1 cells. In addition, the
APC from cdc14-arrested cells has low but reproducibly
higher activity than the completely inactive APC from cdc5
and cdc15 cells [27]. Finally, expression of the Hct1-28A
mutant is able to partially suppress the late mitotic arrest
of the cdc14-1 mutant (Figure 5c), but has no effect on the
growth defects in cdc15-2 and cdc5-1 cells (data not shown).
These lines of evidence all point to the possibility that the
major restraint on APC activity in cdc14-arrested cells is the
presence of inhibitory Hct1 phosphorylation, whereas
additional APC defects prevent cyclin destruction in the
cdc5 and cdc15 mutants (Figure 8).
The ability of Cdc28 and the APC to antagonize each
other’s activity leads to the potential for a regulatory loop
that could enhance the abrupt, all-or-none kinetics of
Cdc28 inactivation in late mitosis. The switch-like fea-
tures of Cdc28 inactivation may also be enhanced by a
similar antagonistic relationship between Cdc28 and its
inhibitor Sic1, the synthesis and stability of which are
inhibited by Cdc28 activity [35–37] (Figure 8). A key issue
remains unresolved, however: what initiating event is
responsible for reducing Cdc28 activity (or increasing APC
or Sic1 activity) to some threshold where these regulatory
relationships bring on rapid and complete Cdc28 inactiva-
tion? Our studies suggest that Cdc14 could help initiate
this process by catalyzing Hct1 dephosphorylation. In
addition, Visintin et al. [33] recently found that Cdc14
dephosphorylates Sic1 (leading to its stabilization) and the
transcription factor Swi5, leading to an increase in SIC1
expression. We suspect that additional mechanisms, prob-
ably involving Cdc5 and Cdc15, also contribute to the late
mitotic decline in Cdc28 activity. 
Materials and methods
Yeast strains and protein methods 
All strains were derivatives of W303. To construct strains for APC purifi-
cation, CDC23–HA from pRS239 (gift from P. Hieter) was integrated at
the CDC23 locus of LH131 (Matα cdc23-1; a gift of L. Hwang) by one-
step gene replacement. A His6 tag was inserted immediately before the
stop codon of CDC16, and this construct was used to replace endoge-
nous CDC16 of SLJ128 (MATa bar1 pep4∆::URA3) with CDC16–His6.
These strains were crossed and sporulated to produce SLJ290 (MATa
bar1 CDC23::CDC23HA CDC16::CDC16-6His-LEU2 pep4∆::URA3).
Additional strains used for APC purification were derived from crosses to
SLJ290. Wild-type and mutant HCT1 genes were cloned into a
pRS304-based plasmid containing the GAL1/10 promoter and a single
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Figure 8
Model of the regulatory system governing Cdc28 inactivation in late
mitosis. This scheme accounts for our evidence that the APC core
undergoes a Cdc5-dependent and Cdc15-dependent increase in Hct1
sensitivity in late mitosis (indicated by an asterisk). Cdc14 is not required
for this process but is required for the activation of APC by Hct1
dephosphorylation. It remains possible that Cdc5 and Cdc15 are also
required for Hct1 dephosphorylation and for upregulation of Sic1 [6,27].
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carboxy-terminal HA tag [27]; these constructs were integrated at the
TRP1 locus of a wild-type, an hct1∆::LEU2 (gift of W. Seufert), a
cdc14-1, or a sic1∆::LEU2 (gift of A. Rudner) strain. For Cdc14 over-
production experiments, the CDC14 gene was cloned into pDK20
[38] under control of the GAL1/10 promoter; this construct was inte-
grated at the URA3 locus of wild-type and sic1∆ strains containing
GAL–HCT1–HA integrated at the TRP1 locus. Yeast lysate prepara-
tion, immunoblotting, immunoprecipitation, and phosphatase treatment
were as described [27,39]. Cyclin–ubiquitin ligase activity of the APC
from yeast extracts was measured as described [6]. Ubiquitination
activity was quantitated on a PhosphorImager using the ImageQuant
program (Molecular Dynamics). 
APC purification
A pellet from 5 × 1010 log-phase cells was resuspended in 50 ml APC
lysis buffer (50 mM Hepes-NaOH pH 7.4, 75 mM KCl, 50 mM NaF,
1 mM MgCl2, 1 mM EGTA, 0.1% NP-40, 10% glycerol, 2 mM phenyl-
methylsulfonylfluoride, 2 µg/ml leupeptin, 2 µg/ml aprotinin, 4 µg/ml
pepstatin) and cells were lysed by bead beating in a Mega Beater
(Biospec) at 4°C. Lysates were clarified by centrifugation for 10 min at
9,000 × g at 4°C followed by ultracentrifugation (1 h, 80,000 × g, 4°C).
The lysate was loaded onto a 5 ml HiTrap Chelating column (Pharma-
cia) charged with cobalt and equilibrated in APC-Buffer A (50 mM
Hepes-NaOH pH 7.4, 200 mM KCl, 50 mM NaF, 0.1% NP-40, 10%
glycerol). Following a wash with APC-Buffer A containing 10 mM imi-
dazole, bound proteins were then eluted with a linear gradient
(10–200 mM) of imidazole in APC-Buffer A. Fractions containing the
APC were pooled, diluted to 50 mM KCl in APC-Buffer B (20 mM Tris-
HCl, pH 7.6, 1 mM MgCl2, 10% glycerol, 1 mM dithiothreitol (DTT)),
and loaded onto a 1 ml HiTrap SP column equilibrated in APC-Buffer B
containing 50 mM KCl. Proteins were eluted with a 50–350 mM KCl
gradient in APC-Buffer B. The APC fractions were pooled, diluted to
100 mM KCl with APC-Buffer C (APC-Buffer B with 0.1% Tween-20),
and loaded onto a 1 ml HiTrap Q column. Following a wash in APC-
Buffer C plus 250 mM KCl, the APC was eluted from the column with a
250–750 mM KCl gradient in APC-Buffer C. Fractions containing the
APC were pooled, diluted with an equal volume of APC-Buffer A, and
repurified on a 1 ml HiTrap Chelating column charged with cobalt.
APC-containing fractions were pooled and insulin (Sigma) was added
to 0.1 mg/ml. The concentration of the purified APC was approximated
based on the silver staining intensity of the Cdc16 band.
Hct1 purification
HCT1 was amplified from genomic DNA by PCR and cloned into
pFB-6His at the NcoI site to create pFB-Hct1H6. The Cdc28 phos-
phorylation site mutant, pFB-Hct1H6-28A, was generated by oligonu-
cleotide-mediated mutagenesis of pFB-Hct1H6 [40] to change serines
16, 42, 227, 239 and 436 and threonine 176 to alanines. Bac-
uloviruses encoding wild-type or mutant Hct1–His6 were generated
using the Bac-to-Bac expression system (Gibco BRL). Wild-type and
mutant Hct1–His6 were purified from baculovirus-infected Sf9 cells by
metal-affinity chromatography as described [41]. Tween-20 (0.1%) and
insulin (0.1 mg/ml) were added prior to storage.
Cdc28–Clb2 purification
To produce an active Cdc28–Clb2 kinase, lysate was prepared from
insect cells co-infected with baculoviruses encoding Cdc28–HA and
Cak1–HA3 (a gift of A. Farrell), and combined with a lysate of bacteria
expressing a Clb2–maltose binding protein (MBP) fusion protein (a gift
of R. Deshaies). The Cdc28–Clb2–MBP complex was then purified on
an amylose column (NEB), followed by cation-exchange chromatogra-
phy (Pharmacia SP Sepharose Fast Flow). Approximately equimolar
amounts of Cdc28 and Clb2 were present in the purified complex.
Cdc14 purification
CDC14 was amplified from genomic DNA by PCR and cloned into the
BamHI site of pGEX-3X (Pharmacia). Bacteria transformed with this con-
struct were grown to an OD600 of 0.6, and expression of GST–Cdc14
was induced with IPTG (0.1 mM) for 16 h at 23°C. The recombinant
protein was purified on a glutathione–sepharose 4B column (Pharmacia),
followed by anion-exchange chromatography (Pharmacia HiTrap Q). Point
mutants in the Cdc14 active site were generated by subcloning CDC14
into pBSSKII+ (Stratagene) for oligonucleotide-directed mutagenesis. 
Phosphorylation of Hct1 by Cdc28–Clb2
Purified Cdc28–Clb2–MBP was incubated for 20 min at 23°C in a
20 µl reaction mixture containing 100 µM ATP, 150 ng Hct1–His6, and
2.5 µCi [γ-32P]ATP (3000 mCi/mmol) in kinase buffer (50 mM Hepes-
NaOH pH 7.4, 10 mM MgCl2, and 1 mM DTT). Reaction products were
analyzed by 8% SDS–PAGE followed by autoradiography. To deter-
mine the effect of Cdc28–Clb2 phosphorylation on Hct–His6, the
Cdc28–Clb2 complex was immobilized on protein-A–sepharose beads
(Sigma) by immunoprecipitation with anti-Clb2 [42] and anti-MBP
(NEB) polyclonal antibodies. Immobilized Cdc28–Clb2 complexes
were used to phosphorylate Hct1–His6 in reactions containing 1 mM
ATP. Following a 30 min incubation at 25°C, Hct1–His6 was separated
from the Cdc28–Clb2 by removal of the beads.
Hct1 phosphate release assay
Hct1–His6 (2.7 µg) was radiolabeled by 20 min incubation at 25°C
with 1.1 µg Cdc28–Clb2 and 100 µCi [γ-32P]ATP (3,000 Ci/mmol) in
a 560 µl reaction. Free ATP was removed by gel filtration on a 4 ml
Sephadex G25 column equilibrated in HBS (25 mM Hepes-NaOH
pH 7.4, 150 mM NaCl, 1 mM DTT), followed by addition of glycerol
(10%) and insulin (0.1 mg/ml). Aliquots of labeled Hct1 (90 ng;
200,000 cpm) were incubated for 5 min at 25°C in 20 µl reactions
with GST or GST–Cdc14, followed by addition of 10 µl BSA
(10 mg/ml) and 180 µl ice-cold 20% trichloroacetic acid. Following
incubation on ice for 30 min, the mixture was centrifuged (16,000 × g,
10 min, 4°C), and 100 µl of the supernatant was removed for quantita-
tion by scintillation counting. 
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